Universal Time: 14:16  |  Local Time: 14:16 (0h GMT)
Select your timezone:
Reset

Sun Sep 13

00:00 Symposium: Lessons Learned about COVID-19
105.4 Immunogenetics (HLA and ABO)
Lori Jeanne West, Canada
105.6 Global Impact of COVID-19 on Transplantation
Alexandre Loupy, France
105.1 Virology, Epidemiology and Clinical Course
Olivia S. Kates, United States
105.2 Organ Specific Involvement of COVID-19
Aneesha Anand Shetty, United States
105.3 Diagnostics:  PCR, Antigen Detection and Serology 
Robin Patel, United States
105.5 Therapeutics & Vaccines
Michael G. Ison, United States
00:00 Symposium: Transplanting in the Era of COVID-19
110.2 When a Recipient with COVID-19 Can Proceed to Transplant
Paolo Antonio Grossi, Italy
110.1 Donor Screening and the Risk of Virus Transmission
Thomas D. Mone, United States
110.4 Transplantation in the Hot Zone
Jean C. Emond, United States
110.3 Lung Transplantation for COVID-19
Jingyu Chen, People's Republic of China
110.5 Transplantation and Ethical Issues in the COVID Era: Doing the right thing depends on location, resources and disease burden
Peter G. Stock, United States
22:00 - 23:30 Workshop Session: Design of Xenotransplantation Clinical Trials
201.1 Cornea
Chang Ho Yoon, Korea
201.2 Naked islets
Kwang-Won Kim, Korea
201.3 Encapsulated islets
Shinichi Matsumoto, Japan
201.4 Kidney
Alfred Joseph Tector, United States

Mon Sep 14

00:15 - 02:00 State-of-the-Art Session: Expanding the Donor Pool, Pushing the Limits
222.2 Use of DCD organs in heart and lung transplant
Gregory I Snell, Australia
222.1 Use of HCV positive organs into HCV negative recipients
David Goldberg, United States
222.3 Transplant outcomes from older donors > Age 60
Colleen L. Jay, United States
00:15 - 02:00 State-of-the-Art Session: Inhaling the Evidence (Lung)
223.1 Increasing allograft utilization and redefining marginality (to include discussion on Hep C, ischaemic time and Ex-situ perfusion)
Alejandro Mario Bertolotti, Argentina
223.2 Surgical strategies for pulmonary hypertension (Allows discussion on surgical strategy of access options/ ON-CPB / ON-ECMO/ Off Pump and post transplant ECMO support)
Jasleen Kukreja, United States
223.3 Survivorship in lung transplantation (there is a constant need to reinforce that the surgical component alone is only a small step in the transplant process)
Hilary J. Goldberg, United States
08:15 - 10:00 State-of-the-Art Session: Managing Immunosuppression When Things Go Wrong
261.1 Managing IS in recipients with a failing graft
Sangho Lee, Korea
261.3 Managing IS in recipients treated for malignancies
Daniel Seron, Spain
261.2 Managing IS in recipients with complex infections
Peter Chin-Hong, United States
13:00 - 14:30 Workshop Session: What is the Ideal Pig for Xenotransplantation? / Carl-Gustav Groth Xeno Prize
276.1 Are remaining xeno-antigens relevant?
Alfred Joseph Tector, United States
276.2 The ideal modified pig, how many genes are necessary?
Eckhard Wolf, Germany
276.3 Do we need to address p?hysiologic incompatibilities
David K. C. Cooper, United States
276.4 Xeno-organ growth: myth or reality?
Matthias Längin, Germany
276.5 Presentation of the Carl-Gustav Groth Xeno Prize to Joachim Hundrieser
Agnes Azimzadeh, United States
22:00 - 23:30 Workshop Session: What the ID Doc should know about …
302.4 Rejection in intestinal transplant
Gabriel E. Gondolesi, Argentina
302.1 CLAD
Gregory I Snell, Australia
302.2 Bilomas
Prema Raj Jeyaraj, Singapore
302.3 Delayed allograft function after renal transplant
Roslyn B Mannon, United States

Tue Sep 15

00:15 - 02:00 State-of-the-Art Session: Metrics for OPO Performance in Organ Donation
321.1 Utilizing administrative data sets to measure OPO performance
Ryutaro Hirose, United States
321.2 Performance measures around the world
Jeremy Chapman, Australia
321.3 Measurements of OPO performance utilizing death record audits in Australia
Helen Opdam, Australia
00:15 - 02:00 Workshop Session: Sex in the Time of SARS-CoV-2 – Relevance to transplantation
323.1 Sex, gender, and their impact on COVID 19
Deborah Clegg, United States
323.2 Sex mAtteRS-CoV-2 in Transplantation
Ruth Sapir-Pichhadze, Canada
323.3 Panelists
Bethany J. Foster, Canada
Biff F. Palmer, United States
Amanda Vinson, Canada
06:00 - 07:30 Workshop Session: Regulation of Xenotransplantation
341.4 Update on the Changsha Communiques
Wayne J. Hawthorne, Australia
341.2 Regulation in China
Shaoping Deng, People's Republic of China
341.1 Regulation in Korea
Ivo Kwon, Korea
341.3 Regulating Safety: what’s new?
Linda Scobie, United Kingdom
07:30 - 08:15 Oral Abstracts Session: Infectious Diseases
353.5 (P-9.02 in Journal) Impact of non-active hepatitis B on patient survival after renal transplantation
Marcel RG Naik, Germany
353.2 A recent diagnosis of tuberculosis is a risk factor for post-transplant morbidity & mortality after liver transplantation: A propensity score match-based analysis
Pradez Sapkota, India
353.3 Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
Hyunwook Kwon, Korea
353.4 Gram negative blood stream infection in renal transplant recipients: Risk factors and outcome from a transplant center in Pakistan
Sunil Kumar Dodani, Pakistan
08:15 - 10:00 State-of-the-Art Session: The Salvage, the Extreme and the Beat Goes On (Heart)
361.3 Surveillance strategies post heart transplantation (current evidence on biopsy vs imaging vs biomarkers)
Peter S. Macdonald, Australia
361.1 Options for bridging to transplantation (advanced HF management / home inotropes/ economic temporary bridging options / LV vent +/-ECMO ….etc)
Anna Meyer, Germany
361.2 Lessons from DCD heart transplantation
Kumud K Dhital, India
08:15 - 10:00 Workshop Session: TTS-WTGF Joint Session: How to harness exercise post – transplantation (Impact) and how to measure patient reported outcomes in the Covid-19 Era
363.1 Introduction and Welcome
Chris Thomas, Australia
363.6 Billion Steps Challenge 2: The Sequel – Using online exercise challenges to engage activity in transplant recipients
Ka-Foon Chau, Hong Kong
363.3 Refit for life (online rehabilitation program) as a way of delivering increased Qalys and outcomes
Liz Schick, Switzerland
363.2 Safety of various sports post transplant to dispel the myth of unacceptable risk in the context of Covid
Paul Harden, United Kingdom
363.4 Potential impact of exercise and sport on patient outcomes
Gareth Wiltshire, United Kingdom
363.5 Results of survey – Organ Transplant recipients health outcomes
Zachary S. Brooks PhD, United States
13:00 - 14:45 Workshop Session: Global Strategies for Facilitating Ethical Practices in Organ Transplantation
377.4 Developing programs in resource constrained areas – Vietnam
Richard Allen, Australia
377.3 Organ transplantation for refugees: The Latin American case
Alejandro Niño Murcia, Colombia
377.5 Combating paid donation in India
Vivek Kute, India
377.8 Strategies for increasing deceased donation in Iran
Seyed Ali Malek Hosseini, Iran (Islamic Republic of)
377.6 Combating paid donation in the Philippines
Benita Padilla, Philippines
377.1 Resident minorities Access to organ donation and transplantation – Middle-East
Riadh Fadhil, Qatar
377.2 Non-resident access to transplantation and impact on local lists – Europe
Beatriz Domínguez-Gil, Spain
377.7 Transplanting the undocumented in the USA
Peter G. Stock, United States
14:30 - 15:15 Oral Abstracts Session: Stem Cell Transplantation and Xenotransplantation
384.2 Quantifying the immune response to tissue engineered extracellular matrix
Ryaan EL-Andari, Canada
384.1 Simple Limbal Epithelial Transplantation (SLET) in a patient with limbal stem cell deficiency
Dilek Dursun Altinors, Turkey
384.3 Successful long-term TMA- and rejection-free survival of a kidney xenograft with triple xenoantigen knockout plus insertion of multiple human transgenes
David Ma, United States
384.4 Evidence for GTKO/β4GalNT2KO pigs as the preferred organ-source for old world monkeys as a preclinical model of xenotransplantation instead of triple-knockout pigs
Takayuki Yamamoto, United States
15:15 - 17:00 State-of-the-Art Session: How Sex Impacts Post-Transplant Course
392.2 Sex differences in infection risks and vaccine responses
Deepali Kumar, Canada
392.1 Sex differences in cancer risk post-transplant
Anna Buxeda, Spain
392.3 Sex and the heart: Major cardiovascular events in transplantation
Darshana Dadhania, United States
22:00 - 23:30 Workshop Session: TTS-ISHLT Joint Symposium: Capacity Building in Transplantation: Meeting Challenges Through Global Partnership
402.3 Establishing ethical and legal standards – From organ trade to presumed consent
Wendy Rogers, Australia
402.4 Emerging programs - Dealing with the challenges of a global pandemic
Saima Aslam, United States
402.2 DCD in heart and lung transplantation – Is there a need for a global standard?
Kumud K Dhital, India
402.1 Collaborative models of organ allocation in an era of populism
Howard J. Eisen, United States
23:30 - 00:15 Oral Abstracts Session: Heart and Lung Abstract Session
413.1 Emerging roles of left ventricular assist device therapy as bridge to transplant in an Asian city with scarce heart transplant donor
KA LAM WONG, Hong Kong
413.2 Comparison of pure antibody-mediated rejection with mixed cellular and antibody-mediated rejection in regards to the pathological features, development of cardiac allograft vasculopathy (CAV) and cardiovascular mortality (CVM) in heart transplant patients
Binnaz Handan Ozdemir, Turkey
413.3 (P-16.05 in the Journal) Does body size affect a successful bridge to heart transplantation by long-term continuous-flow ventricular assist device support?
Minoru Ono, Japan
413.4 Ambient air pollution and waitlist mortality among lung transplant candidates
Mara McAdams DeMarco, United States

Wed Sep 16

00:15 - 02:00 Workshop Session: Upcoming Issues in the Diagnosis of Transplant Rejection
423.3 Dilemmas in renal allograft biopsy diagnosis
Brian J Nankivell, Australia
423.2 Gene expression in transplant tissue and body fluid
Michael Mengel, Canada
423.1 Digital pathology and machine learning in renal transplant pathology
Alton "Brad" Farris, United States
06:00 - 07:30 Workshop Session: Unique Aspects of Organ Donation and Assessment in Pediatric Transplantation
442.1 Risks for the living donor
Michael Kaabak, Russian Federation
442.2 Culture and religious perspectives
Jun Oh, Germany
442.4 ABO- and HLA- Incompatible transplantation
Seiichiro Shishido, Japan
442.3 Challenges of small paediatric donors
Nam-Joon Yi, Korea
08:15 - 10:00 State-of-the-Art Session: Recent Breakthroughs in Xenogeneic Tissue and Organ Transplantation
462.1 Heart
Paolo Brenner, Germany
462.3 Islets
Chung-Gyu Park, Korea
462.4 Cornea
Mee Kum Kim, Korea
462.2 Kidney
Kazuhiko Yamada, United States
08:15 - 10:00 Workshop Session: Innovative Strategies for Eliminating Donor Financial Burdens
463.1 Background : Economic impact, ethics, etc
Jeremy Chapman, Australia
463.2 Australian Perspective
Henry Pleass, Australia
463.3 European Perspective
Paul Harden, United Kingdom
463.4 Developing Country’s Perspective
Ala Ali, Iraq
463.5 US Perspective
Deirdre Sawinski, United States
13:00 - 14:30 Workshop Session: CMV - What's New
477.3 New risks for CMV in solid organ and stem cell transplant recipients
José Maria Aguado, Spain
477.1 New drugs against an old foe
Francisco M Marty, United States
477.2 Immune monitoring
Camille Nelson Kotton, United States
15:15 - 17:00 State-of-the-Art Session: Paediatric Transplantation Around the World
491.1 Paediatric kidney transplantation around the world
Mignon McCulloch, South Africa
491.2 Cost Effective Immunosuppressive Medications Around the World
Katherine Twombley, United States
491.3 Variety of vaccine preventive paediatric infectious diseases around the world
Lara Danziger-Isakov, United States

E-Posters

Poster Session: Cellular and Regenerative Therapies
P-3.06 Generation of stable human induced regulatory T-cells requires optimal rapamycin concentration and TCR stimulation
Juewan Kim, Australia
P-3.11 Small-for-size syndrome is characterized with PD-L1 upregulation in macrophage and blocking PD-L1 accelerates liver regeneration
Ji-Hua Shi, People's Republic of China
P-3.14 Directed differentiation of iPS into imDCs under the action of SN can induce immunoreactivity in vitro
Cuixiang Xu, People's Republic of China
P-3.15 Sinomenine enhances imDC derived from IPS cell-directed differentiation to induce transplant immune hyporesponsiveness in mouse
Cuixiang Xu, People's Republic of China
P-3.03 Cell therapy using CD8+Tregs in human transplantation
Séverine Bézie, France
P-3.10 Bile duct reconstruction using scaffold-free tubular constructs created by a Bio-3D Printer for transplantation
Takashi Hamada, Japan
P-3.13 Visual rehabilitation after penetrating keratoplasty
Leyla Asena, Turkey
P-3.16 Limbal stem cell transplantation for restoration of the ocular surface health in bilateral limbal stem cell deficiency
Dilek Dursun Altinors, Turkey
P-3.01 Mass Cytometry Analysis of the Peripheral Regulatory T cell Compartment after Cellular Therapy in Renal Transplantation
Alaa Alzhrani, United Kingdom
P-3.08 Successful induction of hematopoietic chimerism by MCL-1 and Bcl-2 inhibition without radiation/chemo therapy in nonhuman primates
David Ma, United States
Poster Session: Donation and Procurement
P-4.03 Sharing of deceased donor livers in Australia and New Zealand
Michael Fink, Australia
P-4.04 Removing the BMI bias in kidney transplantation: Outcomes of kidney transplantation in patients with BMI >35
Aaron YS Hui, Australia
P-4.05 Clinician perspectives on factors associated with delayed wait-listing for deceased donor renal transplantation in Australia
Lachlan McMichael, Australia
P-4.10 Missed opportunities for organ donation from potential donors with primary brain tumours in Australia; cohort study 2010-2015
Imogen Thomson, Australia
P-4.12 Verification of suspected melanomas in deceased organ donor referrals: A population-based cohort study using data-linkage, 2010-2015
Brenda Marie Rosales, Australia
P-4.15 It’s not too late to donate...Controlled Donation after Circulatory Death (DCD) of lungs up to 24 hours after Withdrawal of Cardio Respiratory Support (WCRS)
Katherine Labib, Australia
P-4.16 Perceived vs. verified risk of cancer transmission from deceased organ donors: a 2010-2015 cohort study using data linkage in New South Wales, Australia
James A. Hedley, Australia
P-4.51 Kidney Paired Donation In Brazil
Gustavo Fernandes Ferreira, Brazil
P-4.44 Health professional level barriers to living donor kidney transplantation: A mixed methods study
Renata Iskander, Canada
P-4.11 A prediction model of delay graft function from deceased donor risk factor: A multi-center study from China
Wujun Xue, People's Republic of China
P-4.23 Organ donation, a new subject developed in China towards professionalism
Wenshi Jiang, People's Republic of China
P-4.61 Brain death-mediated inflammatory liver injury is mediated by hepatocytes apoptosis through TRAIL
Zhong-kun Huo, People's Republic of China
P-4.56 A systematic review of physicians’ and patients’ preferences regarding the allocation of deceased donor organs: To what extent are physicians acting as advocates for their patients?
Tim Bartling, Germany
P-4.57 Systematic review and focus group discussions of public preferences for the allocation of deceased donor organs as preliminary works: Building a discrete choice experiment evaluating principles of distributive justice
Carina Oedingen, Germany
P-4.35 Asymptomatic donor stones: Management algorithm
Anant Kumar, India
P-4.38 Comparative analysis of live donor kidney transplantation in double renal arteries with 30/70 lumen discrepancy using Pajama Bench reconstruction versus end to side reconstruction and separate implantation technique
Anant Kumar, India
P-4.24 Ten recommendations on approaching next of kin for consenting organ donation; Or How did we manage to increase consent rates by 64%?
Omid Ghobadi, Iran (Islamic Republic of)
P-4.30 National implementation of Persian possible donor detection program: An 8-month efficiency evaluation
Ali Etemadi, Iran (Islamic Republic of)
P-4.49 Minimum incision open donor nephrectomy versus laparoendoscopic single-site donor nephrectomy: A possible safe alternative
Kentaro Ide, Japan
P-4.32 The meaning of kidney transplantation from circulatory death donor in local hospital
Shin Do Suh, Korea
P-4.41 Predictors for renal outcome in living kidney donors: From data of Korean organ transplantation registry
Yunmi Kim, Korea
P-4.48 Living liver donor surgical complication : Single center experience
Eun-Kyoung Jwa, Korea
P-4.40 Comparative analysis of donor and allograft outcomes based on laterality of kidney donation: proof of equivalence of the safety and efficacy of laparoscopic left versus right donor nephrectomy
Dinno Francis A Mendiola, Philippines
P-4.46 Laparoscopic left lateral sectionectomy in living liver donors: From the first experience to routine usage
Konstantin O. Semash, Russian Federation
P-4.65 Does the cold storage really «cold»? Liver thermography and microdialysis findings
Alexander I Sushkov, Russian Federation
P-4.14 Benefits of kidney transplantation in Asians - A comparison of survival of kidney transplant recipients and wait-listed patients remaining on dialysis in Singapore
Terence Kee Yi Shern, Singapore
P-4.19 Experiences with expanded criteria donors: 10-year analysis of the Martin, Slovakia Transplant Center
Ivana Dedinska, Slovakia (Slovak Republic)
P-4.13 Impact of controlled donation after circulatory death (cDCD) on waiting list mortality for liver transplantation in the last 10 years: The Spanish experience
Felipe Alconchel, Spain
P-4.22 ISO quality certification for a hospital-based organ procurement unit: The United Arab Emirates (UAE) experience
María Paula Gómez, Spain
P-4.34 Implementation of a mobile ECMO team for normothermic regional perfusion as donor preservation method in Controlled Donation After Circulatory death (CDAC) in the community of Madrid
ALONSO MATEOS RODRIGUEZ, Spain
P-4.21 Deceased-donor transplantation activities in Turkey
Ebru Hatice Ayvazoglu Soy, Turkey
P-4.07 Histopatological grade of ischemia reperfusion injury on short- and long-term outcomes in liver transplantation using DCD (deceased after circulatory death donor) grafts
Annalisa Dolcet, United Kingdom
P-4.08 Deceased kidney donor pre-procurement cardiac arrest associated with better long-term graft survival
Shivani Bajpai, United States
P-4.18 Zero organ, one organ, and authorized-not recovered donors: Trends and opportunities in a growing organ procurement organization
Jeffrey P. Orlowski, United States
P-4.47 Robotic versus open mini incision living donor nephrectomy: Single center experience
Seung Duk Lee, United States
P-4.62 Bridging the gap: normothermic perfusion of discarded livers significantly alleviates the donor shortage in the United States
Siavash Raigani, United States
P-4.84 Implementation of a national organ matching and data system for Australian solid organ transplantation programs
Rhonda Holdsworth, Australia
P-4.100 Burnout and resilience among organ donation coordinators: A scoping review
Vanessa Silva e Silva, Canada
P-4.102 Bric study - Burnout and resiliency levels among organ donation coordinators: Research protocol
Vanessa Silva e Silva, Canada
P-4.69 Double-lobectomy in rat model of steatotic liver transplantation
Fu Zhen, People's Republic of China
P-4.73 Value of CTGF in assessment of liver graft with non-alcoholic fatty liver disease after brain death
Dongjing Yang, People's Republic of China
P-4.96 Tetramethylpyrazine activated PPARγ in resuscitating the liver graft donated after cardiac death
Fu Zhen, People's Republic of China
P-4.111 Enabling legal provisions and their crucial role in promoting organ donation and transplantation – The Indian scenario
Vasanthi Ramesh M.S., FALS, India
P-4.70 Lessons learned from perfusate analysis during dual hypothermic oxygenated machine perfusion of liver grafts
Damiano Patrono, Italy
P-4.103 The role of cooperation programs including education of tissue and organ transplant coordinators and collaboration with Japan Organ Transplant Network on heart valve donation in west Japan
Norihide Fukushima, Japan
P-4.107 Deceased donor tissue recovery activity in Eastern Japan
Sayaka Nagashima, Japan
P-4.101 Causes of lowered family consent rate for organ donation
Eunsuk Yu, Korea
P-4.87 Brain death donation improvement areas: Procurement impact
Olga E Facio, Mexico
P-4.74 Observations on 24-hour ex situ normothermic liver perfusion
Amelia J Hessheimer, Spain
P-4.80 New technique for abdominal wall retrieval: Our initial outcomes with the new technique in non-vascularized fascia
Iago Justo Alonso, Spain
P-4.81 Quorum: IT tool for organ donation quality system management: Pilot program in the Kingdom of Saudi Arabia
Estephan Arredondo, Spain
P-4.82 Implementation results of the first hospital-based organ procurement unit in Kerala (India)
María Paula Gómez, Spain
P-4.92 Protocol based on hepatitis C virus nucleic acid testing to optimize renal transplant from seropositive donors to seronegative recipients. An European experience
antonio franco, Spain
P-4.98 International Registry In Organ Donation and Transplantation (IRODAT) – 2019 worldwide data
María Paula Gómez, Spain
P-4.99 Heart transplantation from controlled donors: First case report in Spain
ALONSO MATEOS RODRIGUEZ, Spain
P-4.83 Readiness of the retrieval team for deceased donor kidney transplantation in Thailand
Korntip Phonphok, Thailand
P-4.94 Evaluation of one year, five years and ten years life time of patients with kidney transplant: Single-center experience
Mehmet Fethullah Aydin, Turkey
P-4.110 Establishment of solid organ transplantation in the United Arab Emirates
Shiva Kumar, United Arab Emirates
P-4.112 Establishment of liver transplantation in the United Arab Emirates from deceased and living donors
Shiva Kumar, United Arab Emirates
P-4.66 Real-time viability assessment during normothermic machine perfusion with Raman spectroscopy
Reinier de Vries, United States
P-4.76 Using pulsatile perfusion to successfully transplant kidneys with 15 percent glomerulosclerosis
Marty T Sellers, United States
P-4.77 Deceased donor organ flush with equivalent volumes of HTK and UW at a single U.S. organ procurement organization
Richard S. Mangus, United States
P-4.79 Automated electronic referrals are changing donation
Wade Liu, United States
P-4.89 Salvaging discarded livers with normothermic machine perfusion: Is it worth the cost?
Reinier de Vries, United States
P-4.95 Liver transplantation of hepatitis C-viremic donors to hepatitis C naive recipients
Fidel Lopez-Verdugo, United States
P-4.97 Aggressive pursuit of liver only donors and their transplant outcomes: Should we continue?
Marty T Sellers, United States
P-4.109 Pancreas transplant in chronic kidney disease for type 1 diabetic patients
Rashikh A Choudhury, United States
P-4.85 Robotic versus laparoscopic living donor nephrectomy: A prospective study
Thanh-Tuan Nguyen, Viet Nam
Poster Session: Thoracic (Heart and Lung)
P-16.24 Outcomes following extracorporeal photopheresis for chronic lung allograft dysfunction following lung transplantation: A single centre experience
Jaideep Vazirani, Australia
P-16.27 Scedosporium apiospermum and lomentospora prolificans in lung transplant patients: A single centre experience over 24 years
Jaideep Vazirani, Australia
P-16.11 Cancer risk in heart or lung transplant recipients: a meta-analysis
Fan Ge, People's Republic of China
P-16.06 Long-term results of everolimus on renal function and rejection after heart transplantation in a real-life scenario
Markus J. Barten, Germany
P-16.09 Left ventricular assist device explantation after cardiac recovery
Christian Heim, Germany
P-16.16 Optimal dosing of cyclosporine and tacrolimus to improve medication adherence and to reduce drug costs after heart transplantation
Markus J. Barten, Germany
P-16.12 External validation of current international short- and long-term prognostic models for survival in heart transplant recipients using marginal donor hearts at single Japanese center
Nobuichiro Yagi, Japan
P-16.13 Transplantation of heart-valve and vascular allografts for cardiovascular surgery: Retrospective analysis of the tissue bank registry data for more than 20 years
Akihiro Masuzawa, Japan
P-16.17 Usefulness of basiliximab use for long waiting heart transplant recipients
Noriko Kikuchi, Japan
P-16.23 Successful lung and liver co-transplantation in pediatric patient with dyskeratosis congenita
SAMINA PARK, Korea
P-16.15 Infectious complications early-term after heart transplantation
Maria Simonenko, Russian Federation
P-16.10 Combined heart-liver transplantation: Single center experience
Amit Sharma, United States
P-16.18 Combined heart-kidney transplantation: single center experience
Amit Sharma, United States
P-16.26 Pregnancy outcomes in 36 lung transplant recipients
Lisa Coscia, United States
P-16.25 Lung transplant programs in developing countries: challenges and solutions
Anh T Nguyen, Viet Nam
P-16.28 Lung transplantation during the outbreak of Coronavirus disease 2019: Early experience from China
Jingyu Chen, People's Republic of China
P-16.30 Long-term diagnostic analysis of invasive pulmonary aspergillosis after solid organ transplantation: Spectrum of initial and follow-up CT findings
Omer Koray Hekimoglu, Turkey

WebApp Sponsor

© 2020 TTS 2020